atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30
Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase